Dr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of ...

Dr. Reddy's Laboratories Ltd. closed 7.02% short of its 52-week high of 1,420.20 rupees, which the company achieved on August ...

Dr. Reddy's Labs ADR saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 0% to 16%.

Alvotech and Dr Reddy's entered into a collaboration and license agreement to co-develop, manufacture and commercialize a ...

HSBC upgraded Dr. Reddy’s Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from ...

Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of ...

CHENNAI: Shares of Dr Reddy’s Laboratories surged over 3% in early trade on Thursday after the Indian drug maker announced a ...

Dr. Reddy's Laboratories Ltd. closed 9.17% short of its 52-week high of 1,420.20 rupees, which the company reached on August ...

LIC’s shareholding in Dr. Reddy’s Laboratories rose from 5.6% at the end of September 2024 to 6.5% by December 2024, and ...

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

Stocks including Bajaj Finserv, IREDA, Coal India, Dr Reddy's Labs, Praj Industries, JSW Energy, SpiceJet, Ashoka Buildcon ...

Life Insurance Corporation of India’s stake in Dr. Reddy’s Laboratories raced past the 8% mark recently with the country’s ...